Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin

Annals of Emergency Medicine

Volumn 61, Issue 4, 2013, Pages 475-479

  Berger, Russell ^a,b   Salhanick, Steven D ^a,c   Chase, Maureen ^a,c   Ganetsky, Michael ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; FRESH FROZEN PLASMA; WARFARIN;

ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; DEMOGRAPHY; DISEASE COURSE; EMERGENCY WARD; ENDOSCOPY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84876584967     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2013.02.008     Document Type: Article

References (7)

1. Melnikova I. The anticoagulants market. Nat Rev Drug Discov. 2009;8:353-354.
2. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281-287.
3. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864-866.
4. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365:2039-2040.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
6. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
7. Beasley BN, Unger EF, Temple R. Anticoagulant options -why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.